Answers are grounded in this paper and cite their sources.
Glutaric aciduria type I (GA-1) is a severe metabolic disorder caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH), leading to accumulation of organic acids in the brain and resulting in striatal injury and progressive movement disorders. Although early diagnosis and dietary management reduce risk, one-third of patients still develop debilitating neurological complications. We previously demonstrated that liver-specific deletion of aminoadipate semialdehyde synthase (AASS), an upstream enzyme in lysine degradation, is a promising therapeutic strategy. Here, we tested an N -acetylgalactosamine (GalNAc)–conjugated siRNA against Aass . Treatment of neonatal Gcdh −/− mice rescued lethality and improved the brain pathology while reducing toxic metabolites in the brain and other organs. Serum biomarkers, including glutaric acid, 3-hydroxyglutaric acid, and glutarylcarnitine, predicted neurological outcomes, supporting their use for therapeutic monitoring. Although systemic metabolite concentrations declined, their urinary excretion remained elevated, consistent with a renal washout phenomenon and preserved excretory capacity. These findings demonstrate the potential of liver-targeted small interfering RNA (siRNA) therapy as a treatment for GA-1.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: